lifestyle.sourcefed.com

Author: Zhongshan Kangfang Biological Medicine Co., LTD

Akeso’s Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer’s Disease Clinical Trials in China

November 19, 2025
Akeso’s Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer

November 5, 2025